The research tackles a well-known bottleneck. Traditional experimental screening is expensive, slow, and constrained by the chemical diversity of available compound libraries. Computational models that estimate biological activity directly from molecular structure—known as quantitative structure–activity relationship, or QSAR, models—promise a faster route, but their reliability depends heavily on how they are built. The authors note that many published QSAR efforts suffer from insufficient feature optimization and ambiguity about whether the task is regression, predicting a continuous activity value, or classification, sorting compounds into active and inactive categories. That ambiguity undermines both interpretability and the consistency of performance evaluation.

To address these problems, the team assembled a dataset of 532 structurally diverse compounds with experimentally reported analgesic activity values drawn from published literature. Each molecule was characterized by 227 molecular descriptors spanning constitutional, topological, geometrical, electronic, and physicochemical properties. The activity score was treated as a continuous target for regression, while a statistically derived threshold converted it into a binary active-or-inactive label for classification. Before training, all inputs were normalized with min–max scaling so that no single feature dominated the learning process.

The most consequential step was feature selection. Using a stepwise elimination procedure, the researchers iteratively removed low-importance descriptors while monitoring model performance, combining the Pearson correlation coefficient with a relative prediction error metric as the selection criterion. The descriptor set shrank from 227 variables to 105, and the effect was unambiguous: predictive performance improved steadily as weakly correlated features were pruned, reaching an optimum at 105 descriptors before declining beyond that point. The retained features describe molecular connectivity, polarity, and hydrogen-bonding potential—properties known to modulate receptor binding affinity and pharmacodynamic behavior. The result is a leaner model that generalizes better, trains faster, and resists overfitting, a chronic hazard in high-dimensional neural modeling.

The network itself is a feed-forward multilayer perceptron implemented in MATLAB, with an input layer of 72 neurons feeding three hidden layers of 22, 9, and 2 neurons, each using the hyperbolic tangent sigmoid activation function, and a single linear output neuron. Hyperparameters, including the number of hidden neurons, learning rate, and regularization factors, were tuned through grid search to minimize the average absolute relative error. Training relied on the Levenberg–Marquardt algorithm, a second-order optimization method prized for its rapid convergence and stability in nonlinear parameter spaces. The final model converged in fewer than 50 iterations, outperforming conventional gradient-descent training in both speed and stability, and regression plots showed near-linear agreement between predicted and experimental values across both training and validation sets.

The headline numbers place the model among the best-performing approaches reported for comparable QSAR tasks. Comparable studies using shallow or single-hidden-layer networks typically report correlation coefficients between 0.85 and 0.93. This framework achieved R = 0.959 for regression and 98.01 percent accuracy for classification. In their comparative analysis, the authors contrast their results with deep neural networks used for triple-negative breast cancer inhibitor and GPCR agonist discovery, multilayer perceptrons classifying lung surfactant inhibitors, principal-component neural networks applied to 95 analgesic compounds, and multiple linear regression models built on small sets of pyrimidine derivatives. They attribute their edge to the joint optimization of architecture and feature selection, which together improved the model’s capacity to capture complex nonlinear structure–activity relationships.

What elevates the work beyond raw predictive power is its attention to interpretability. The descriptor classes retained by the model—molecular connectivity indices, polarity-related parameters, hydrogen-bonding capacity, and lipophilicity descriptors—are tied to receptor accessibility, membrane permeability, and ligand–target interaction potential, the very factors that govern analgesic potency. This gives medicinal chemists a foothold for rational compound optimization rather than a black-box score. The authors are candid about the limits, however: because neural networks are inherently nonlinear, complete mechanistic interpretability remains out of reach, and they propose incorporating explainable AI methods or fragment-level attribution analysis in future iterations to extract deeper structural insight.

The team also acknowledges a gap in the competitive landscape. Modern ensemble methods such as Random Forest and gradient boosting can achieve competitive performance on moderate-sized datasets while offering better interpretability, but benchmarking against them fell outside the scope of the present study—a limitation the authors explicitly flag, with comparative evaluation planned as future work. They are equally clear that the model is computational and does not replace experimental validation. Its purpose is to reduce experimental burden by prioritizing compounds before laboratory testing, and prospective validation on newly designed or synthesized molecules is identified as the critical next step for translational applicability.

There is also a sustainability dimension. By cutting dependence on exhaustive laboratory screening, the framework aligns with eco-efficient pharmacological innovation—minimizing experimental waste while enabling broader exploration of chemical space. The authors frame the hybrid feature-selection-plus-neural-network strategy as a reliable, interpretable, and resource-conscious approach to predictive pharmacology, one that complements rather than replaces experimental workflows and remains compatible with translational drug development strategies.

Looking ahead, the researchers outline several extensions: adapting the optimized framework to other pharmacological classes, implementing transfer learning for multitarget predictions, and integrating explainable AI tools to illuminate mechanism. For a field where the vast majority of early-stage candidates never reach the clinic, a model that can reliably flag the most promising analgesic candidates before synthesis—while explaining, at least in part, which molecular features drive its predictions—represents a meaningful step toward faster, cheaper, and more rational drug discovery. The dataset itself is restricted by licensing agreements and cannot be redistributed, but the methodological blueprint—rigorous descriptor reduction, explicit task definition, and systematic architecture optimization—offers a template other labs can follow as artificial intelligence continues to reshape how new medicines are found.

Subject of Research: Deep learning-based QSAR modeling for predicting analgesic activity in early-stage drug discovery

Article Title: Integrative deep learning strategies to enhance early-stage drug discovery: optimizing computational structure–activity modeling for pharmacotherapeutic innovation

Article References: Rezazi, S., Si-Moussa, C., & Hanini, S. (2026). Integrative deep learning strategies to enhance early-stage drug discovery: optimizing computational structure–activity modeling for pharmacotherapeutic innovation. Journal of Pharmacy & Pharmaceutical Sciences, 29, Article 16155. https://doi.org/10.3389/jpps.2026.16155

Image Credits: AI Generated

DOI: 10.3389/jpps.2026.16155

Keywords: artificial intelligence, drug discovery, QSAR, neural networks, analgesics, molecular descriptors, feature selection, Levenberg-Marquardt algorithm, virtual screening, pharmacology, predictive modeling, medicinal chemistry

The research, published as an open-access article in BMC Complementary Medicine and Therapies, was conducted by a team of Korean medicine researchers led by Ji-eun Yu of Pusan National University and Yohan Choi, Hanbit Jin, Eunji Ahn and corresponding author Dongsu Kim of Dongshin University. Rather than running a clinical trial, the investigators turned to one of the most powerful tools available in Korean health research: the National Health Insurance Service National Sample Cohort, a large, de-identified database drawn from the claims records of the country’s single-payer health system. Because virtually every medical encounter in South Korea generates an insurance claim, this cohort allows researchers to track diagnoses, prescriptions and healthcare visits across millions of citizens with a completeness that few other data sources can match.

The study design was a retrospective cohort analysis. The researchers identified patients diagnosed with gastric cancer and assigned each person an index date anchored to that diagnosis. They then looked backward one year to characterize each patient’s baseline healthcare utilization, including total outpatient visits, and forward one year to measure outcomes. Patients were classified as Korean medicine users if they received outpatient Korean medicine services during the defined exposure window; everyone else was treated as a non-user. This distinction matters because Korean medicine in South Korea is not a fringe practice. It encompasses herbal medicine prescriptions, acupuncture, moxibustion and other therapies delivered by licensed practitioners in dedicated clinics, and it occupies a formal, regulated place in the national health system.

The outcomes the team examined came in two distinct forms, and that distinction turned out to be the intellectual heart of the paper. The first outcome was binary: whether a patient used any analgesics, or any opioids, at all during the follow-up year, recorded simply as yes or no. The second outcome was a count: the number of analgesic prescriptions and the number of opioid prescriptions each patient received over the same period. Separating these two measures allowed the researchers to ask two different questions. Does Korean medicine change whether a cancer patient ends up on pain medication? And does it change how much pain medication that patient receives?

To answer those questions credibly, the investigators had to confront a stubborn methodological problem that plagues nearly all observational research on complementary therapies: confounding by indication and by healthcare behavior. Patients who seek out Korean medicine are, almost by definition, different from those who do not. They tend to be heavier users of healthcare in general, they may have different symptom profiles, and they may hold different attitudes toward medication. If those differences are not accounted for, any apparent association between Korean medicine and painkiller use could simply reflect the underlying characteristics of the patients rather than any effect of the treatment itself.

The team addressed this with multivariable regression analyses that adjusted for a broad set of demographic and clinical characteristics, including measures of healthcare utilization in the year before the index date. They went further, running sensitivity analyses with stricter definitions of what counted as Korean medicine use, to test whether the results depended on how liberally the exposure was defined. They also performed stratified analyses, dividing the cohort into quartiles of total outpatient visits during the exposure window and re-examining the association within each stratum. Supplementary tables in the published article document the ATC codes used to define analgesics and opioids, the distribution of annual prescription counts, and the model-based predicted outcomes for each group, giving readers an unusually transparent view of the analytical machinery behind the headline findings.

What emerged was a nuanced and, in some ways, counterintuitive result. Korean medicine use was not significantly associated with the likelihood that a gastric cancer patient would use analgesics or opioids at all during follow-up. In other words, patients who used Korean medicine were not meaningfully more or less likely than non-users to end up taking pain medication in the first place. But when the researchers turned to the intensity of medication use, a different picture appeared. In the adjusted analyses, Korean medicine use was associated with significantly lower prescription counts for both analgesics and opioids. The association was with the volume of prescribing, not the presence of prescribing.

The authors interpret this pattern as suggesting that Korean medicine may play a complementary role in medication-based pain management, one that operates on the medication burden rather than on whether medication is used. For patients living with cancer, that distinction could carry real clinical weight. Long-term analgesic and opioid use is associated with a cascade of concerns, including adverse drug events, drug interactions with chemotherapy agents, constipation, sedation and the risk of dependence. If a complementary therapy were to reduce the number of prescriptions a patient needs over a year of care, even without eliminating the need for pain drugs entirely, it could meaningfully lighten that pharmacological load. The stratified analyses, which examined the association within quartiles of prior outpatient visit intensity, were designed in part to check whether this signal simply reflected differences in how often patients see doctors, and the sensitivity analyses using stricter exposure definitions tested the robustness of the classification itself.

At the same time, the researchers are careful about what their study can and cannot show. As a retrospective analysis of insurance claims, it captures associations, not causal effects. It cannot reveal whether patients used Korean medicine because their pain was already better controlled, whether herbal prescriptions or acupuncture directly modulated pain, or whether unmeasured differences between user and non-user groups still shaped the results. Claims data also record prescriptions, not necessarily consumption, and they cannot capture over-the-counter medication use. The authors explicitly call for further studies to confirm the findings and to elucidate the underlying mechanisms, a caution that is standard in this field but particularly warranted given the complexity of cancer pain and the heterogeneity of Korean medicine practice itself.

Nevertheless, the study adds a genuinely useful data point to an international conversation about integrative oncology and opioid stewardship. Conducted under the Declaration of Helsinki with approval from the Institutional Review Board of Dongshin University, and funded by the Korea Health Industry Development Institute through grants from the Ministry of Health and Welfare, it exemplifies the kind of large-scale, claims-based evidence that health systems with integrated traditional medicine can generate. For the growing number of gastric cancer patients who already use Korean medicine alongside conventional care, the findings suggest that such use is associated with a lighter prescription burden rather than a change in whether painkillers are used at all. For policymakers weighing how complementary therapies fit into cancer care pathways, the message is subtler: the value of traditional medicine in this context may lie not in replacing conventional analgesia, but in reducing how much of it patients ultimately need. Confirming that promise will require prospective studies, but this analysis provides a rigorous starting point built on national-scale data.

Subject of Research: The association between traditional Korean medicine use and analgesic and opioid utilization in gastric cancer patients

Article Title: Association between Korean medicine use and analgesic and opioid utilization among patients with gastric cancer

Article References: Yu, J.-E., Choi, Y., Jin, H., Ahn, E., & Kim, D. (2026). Association between Korean medicine use and analgesic and opioid utilization among patients with gastric cancer. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05583-0

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05583-0

Keywords: Korean medicine, gastric cancer, analgesics, opioids, pain management, complementary and alternative medicine, National Health Insurance Service, retrospective cohort study, prescription counts, integrative oncology, healthcare utilization, South Korea